



TABLE OF CONTENTS

FOREWORD1

EXECUTIVE SUMMARY11

I. INTRODUCTION23

II. THE WTO AGREEMENTS RELEVANT TO HEALTH25

A. INTRODUCTION25

 (i) The institution25

 (ii) Structure25

 (iii) Objective26

 (iv) Basic function26

 (v) Membership and accession28

B. KEY WTO PRINCIPLES28

 (i) Most-favoured-nation (MFN): treating other WTO Members equally29

 (ii) National treatment: Treating foreigners and locals equally29

 (iii) The MFN principle and public health30

 (iv) Health exceptions in GATT and GATS30

C. TECHNICAL BARRIERS TO TRADE32

 1. The TBT Agreement32

 (i) Overall objective, purpose of Agreement, and scope32

 (ii) Principles33

 (iii) Examples as applied to health33

 (iv) Use of international health standards33

 (v) Review of the TBT Agreement34

 2. The SPS Agreement34

 (i) Rationale for the SPS Agreement34

 (ii) SPS directly relevant to health35

 (iii) Difference in coverage compared to TBT Agreement35

 (iv) Why is it important which Agreement applies?36

 (v) Scientific justification37

 (vi) Provisional measures37

 (vii) Review38

D. INTELLECTUAL PROPERTY AND TRADE (TRIPS)38

 (i) Provisions for public health protection41

 (ii) What are Member governments' obligations with respect to pharmaceutical patents under TRIPS?42



(iii)	A patent is not a permit to put a product on a market44
(iv)	Research exception and "Bolar" provisions44
(v)	Compulsory licensing and government use45
(vi)	Parallel imports and "exhaustion" of rights45
(vii)	Developing countries' transition periods - Year 2000 for most46
E.	SERVICES (GATS)47
(i)	GATS general obligations49
(ii)	Country options for GATS commitments in health services50
F.	SOLVING DISPUTES52
III.	SPECIFIC HEALTH ISSUES AND WTO AGREEMENTS57
A.	INTRODUCTION57
B.	INFECTIOUS DISEASE CONTROL58
(i)	The link between trade and infectious disease control58
(ii)	International Health Regulations (IHR) - a global regulatory framework59
(iii)	Trade rules are unlikely to restrict governments' actions to control infectious diseases, but do impose some disciplines59
(iv)	Revising the IHR to cope with new threats to health61
C.	FOOD SAFETY62
(i)	Global incidence of food borne disease...62
(ii)	... and the link to trade63
(iii)	The SPS Agreement is perhaps the closest "match" between a health issue (in this case food safety) and trade65
(iv)	How is the WTO "used" to address food safety concerns?65
(v)	The use of "precaution" in food safety67
(vi)	Challenges for the future68
(vii)	Safety of Genetically Modified Products (GMOs)69
D.	TOBACCO CONTROL71
(i)	The threat71
(ii)	Openness to trade may increase consumption of tobacco71
(iii)	Tobacco control policies72
(iv)	Tobacco dispute: an example of the application of trade rules73
(v)	Links between WTO Agreements and Tobacco Policies75
(vi)	Framework Convention on Tobacco Control - a new international health treaty76



(vii)	The FCTC negotiations are a good example of the need for international cooperation77
E.	ENVIRONMENT77
(i)	The link between environment, health and trade77
(ii)	"Like products"79
(iii)	The Asbestos Case - public health takes precedence over trade82
(iv)	Domestically prohibited goods84
(v)	The WTO Committee on Trade and Environment ("the CTE")85
(vi)	Multilateral Environmental Agreements (MEAs)86
F.	ACCESS TO DRUGS AND VACCINES87
(i)	Many measures will make drug prices more affordable88
(ii)	Import duties and tariffs on pharmaceuticals88
(iii)	Impact of patent protection and the TRIPS Agreement on the availability of drugs89
(iv)	Patent protection provides incentives for R&D into new drugs91
(v)	Concern that TRIPS could lead to higher prices for some drugs94
(vi)	However, the TRIPS Agreement contains public health safeguards...97
(vii)	The right to use compulsory licensing under the TRIPS Agreement, and the issue of parallel imports: experiences of some countries103
(viii)	TRIPS and access to medicines - positions taken in some other international fora107
(ix)	WTO Discussions on TRIPS and access to drugs108
G.	HEALTH SERVICES111
(i)	The issues111
(ii)	Trade in health services provides opportunities112
(iii)	... but there are risks112
(iv)	GATS Commitments113
(v)	Effects of country GATS commitments on health services117
(vi)	The exception for governmental services ("carve-out")118
(vii)	Trade liberalization as a risk to quality, equity and other public policy objectives?119
(viii)	GATS recognizes the right to regulate120
(ix)	but regulatory capacity may be weak or non-existent in some developing countries121
(x)	Liberalization calls for greater regulation121
(xi)	The on-going GATS negotiations provide an opportunity for input122



H.	FOOD SECURITY AND NUTRITION124
(i)	Nutrition and health124
(ii)	Food security and nutrition124
(iii)	Trade liberalization and national food security125
(iv)	Food aid127
(v)	The ongoing negotiations represent an opportunity128
I.	EMERGING ISSUES129
1.	Biotechnology129
(i)	Concern about patents130
(ii)	Food security and safety131
(iii)	The Cartagena Biosafety Protocol132
2.	Information technology133
3.	Protection of traditional medicine knowledge134
IV.	TOWARDS HEALTH AND TRADE POLICY COHERENCE137
A.	INTRODUCTION137
B.	TOWARDS POLICY COHERENCE AT NATIONAL AND INTERNATIONAL LEVELS138
(i)	Thailand139
(ii)	Canada141
C.	INTERNATIONAL HEALTH-TRADE COORDINATION BETWEEN THE WHO AND WTO142
D.	CONCLUSION144
(i)	Addressing health issues in WTO rules145
(ii)	... and trade issues in international health rules146
(iii)	The need for evidence to inform policy147
(iv)	Negotiation and reviews147
(v)	Accession148
(vi)	Capacity-building148
(vii)	Two critical ingredients to policy coherence149
ANNEX151

CHARTS AND TABLES

Chart 1	WTO Structure27
Box 1	The definition of an SPS measure at a glance36
Box 2	The relevance of trademarks and "undisclosed information" to health40
Box 3	Counterfeit drugs40



Box 4	Health applications of GATS services modes48
Chart 2	The Panel process55
Box 5	Specific health issues and most relevant WTO agreements58
Box 6	Safety of imported fish during a cholera outbreak60
Box 7	SPS and Codex64
Box 8	EC - Hormones WTO Panel on European Community - Measures concerning meat and meat products (hormones), complaints by the United States and Canada66
Box 9	Article 5.7 of the SPS Agreement67
Box 10	WTO dispute: Thailand - Cigarette case74
Box 11	United States - Standards for reformulated and conventional gasoline (WT/DS2)80
Box 12	European Communities - Measures affecting asbestos and asbestos containing products (WT/DS135)83
Box 13	Uganda ends "malaria taxes"89
Box 14	Effect of the patent system in promoting the invention, development and marketing of new drugs92
Box 15	What is the difference between vaccines and other pharmaceuticals in the context of TRIPS?97
Box 16	WTO dispute: Canada - Patent protection of pharmaceutical products, complaint by the European Communities (WT/DS114/1)98
Box 17	US White House Executive Order 13155, May 20, 2000 - Access to HIV/AIDS pharmaceuticals and medical technologies104
Box 18	Declaration on the TRIPS Agreement and public health109
Table I	WTO Members' commitments on medical, hospital and other health services, and on health insurance (number of Members), 3rd Quarter 2000116
Box 19	Some trade and health issues in WTO bodies and other international fora144